Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo

Cited by (763)

Items 101–200 of 763

1. Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine
   Sinthujan Jegaskanda, Patrick C. Reading, Stephen John Kent · 2014 · The Journal of Immunology
2. Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site
   Strauch, Eva-Maria, Bernard, Steffen M, La, David, Bohn, Alan J, Lee, Peter S, Anderson, Caitlin E, Nieusma, Travis, Holstein, Carly A, Garcia, Natalie K, Hooper, Kathryn A et al. · 2017 · Nature Biotechnology
3. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses
   Peter H. Goff, Tomoko Hayashi, Luis Martínez‐Gil, Maripat Corr, Brian Crain, Shiyin Yao, Howard Brinkerhoff Cottam, Michael Chan, Irene Ramos, Dirk Eggink et al. · 2015 · Journal of Virology
4. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease
   Christopher D. Petro, Pablo A. González, Natalia Cheshenko, Thomas A. Jandl, Nazanin Khajoueinejad, Angèle Bénard, Mayami Sengupta, Betsy C. Herold, William R. Jacobs · 2015 · eLife
5. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
   Estefanı́a Fernández, Wanwisa Dejnirattisai, Bin Cao, Suzanne M. Scheaffer, Piyada Supasa, Wiyada Wongwiwat, Prabagaran Esakky, Andrea M. Drury, Juthathip Mongkolsapaya, Kelle H. Moley et al. · 2017 · Nature Immunology
6. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact
   Paul E. Leon, Wenqian He, Caitlin E. Mullarkey, Mark J. Bailey, Matthew S. Miller, Florian Krammer, Peter Palese, Gene S. Tan · 2016 · Proceedings of the National Academy of Sciences
7. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
   Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, Jérémie Prévost, William David Tolbert, Kelly Symmes, Shilei Ding, Mehdi Benlarbi, Shang Yu Gong, Alexandra Tauzin et al. · 2022 · Cell Reports
8. Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans
   Sarah F. Andrews, Michael Gordon Joyce, Michael James Chambers, Rebecca A. Gillespie, Masaru Kanekiyo, Kwanyee Leung, Eun Sung Yang, Yaroslav Tsybovsky, Adam K. Wheatley, Michelle C. Crank et al. · 2017 · Science Immunology
9. Advances in Universal Influenza Virus Vaccine Design and Antibody Mediated Therapies Based on Conserved Regions of the Hemagglutinin
   Florian Krammer, Peter Palese, John Steel · 2014 · Current topics in microbiology and immunology
10. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner
    Caitlin E. Mullarkey, Mark J. Bailey, Diana Golubeva, Gene S. Tan, Raffael Nachbagauer, Wenqian He, Kyle E. Novakowski, Dawn M. E. Bowdish, Matthew S. Miller, Peter Palese · 2016 · mBio
11. NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies
    Lizdany Flórez‐Álvarez, Juan Carlos Hernández, Wildeman Zapata · 2018 · Frontiers in Immunology
12. Development of a Universal Influenza Vaccine
    Leonardo D. Estrada, Stacey Schultz‐Cherry · 2019 · The Journal of Immunology
13. M2-based influenza vaccines: recent advances and clinical potential
    Annasaheb B. Kolpe, Bert Schepens, Walter C. Fiers, Xavier Saelens · 2016 · Expert Review of Vaccines
14. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
    Weina Sun, Yonghong Liu, Fatima Amanat, Irene González‐Domínguez, Stephen McCroskery, Stefan Slamanig, Lynda Coughlan, Victoria C. Rosado, Nicholas Lemus, Sonia Jangra et al. · 2021 · Nature Communications
15. Animal Models for Influenza Viruses: Implications for Universal Vaccine Development
    Irina Margine, Florian Krammer · 2014 · Pathogens
16. The continued advance of vaccine adjuvants – ‘we can work it out’
    Derek T. O’Hagan, Rushit N. Lodaya, Giuseppe Lofano · 2020 · Seminars in Immunology
17. TRIM 21: a cytosolic Fc receptor with broad antibody isotype specificity
    Stian Foss, Ruth Watkinson, Inger Sandlie, Leo C. James, Jan Terje Andersen · 2015 · Immunological Reviews
18. Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model
    Mark J. Bailey, James E. Duehr, Harrison Dulin, Felix Broecker, Julia A. Brown, Fortuna Arumemi, Maria C. Bermúdez González, Victor Hugo Leyva-Grado, Matthew J. Evans, Viviana R. Simon et al. · 2018 · Nature Communications
19. Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens
    Seth J. Zost, Nicholas C. Wu, Scott E. Hensley, Ian A. Wilson · 2018 · The Journal of Infectious Diseases
20. Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG
    Bruce D. Wines, Hillary A. Vanderven, Sandra E. Esparon, Anne B. Kristensen, Stephen John Kent, Philip Mark Hogarth · 2016 · The Journal of Immunology
21. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA
    Sandhya Bangaru, Honglin Zhang, Iuliia M. Gilchuk, Thomas G. Voss, Ryan P. Irving, Pavlo Gilchuk, Pranathi Matta, Xueyong Zhu, Shanshan Lang, Travis Nieusma et al. · 2018 · Nature Communications
22. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery
    Kelsey A. Gregg, Erin M. Harberts, Francesca M. Gardner, Mark R. Pelletier, Corinne Cayatte, Li Yu, Michael P. McCarthy, Jason D. Marshall, Robert K. Ernst · 2017 · mBio
23. Vaccine molecules targeting Xcr1 on cross‐presenting DCs induce protective CD8 + T‐cell responses against influenza virus
    Even Fossum, Gunnveig Grødeland, Dorothea Terhorst‐Molawi, Anders Aune Tveita, Elisabeth Lea Vikse, Siri Mjaaland, Sandrine Henri, Bernard MALISSEN, Bjarne Bogen · 2014 · European Journal of Immunology
24. Designing a multi-epitope vaccine to provoke the robust immune response against influenza A H7N9
    Hossein Tarrahimofrad, Somayyeh Rahimnahal, Javad Zamani, Ehsan Jahangirian, Saeed Aminzadeh · 2021 · Scientific Reports
25. B Cell Activation and Response Regulation During Viral Infections
    Jonathan H. Lam, Fauna Leah Smith, Nicole Baumgarth · 2020 · Viral Immunology
26. Novel universal influenza virus vaccine approaches
    Florian Krammer · 2016 · Current Opinion in Virology
27. Protective Antibodies Against Influenza Proteins
    Herbey Oswaldo Padilla-Quirarte, Delia Vanesa López-Guerrero, Lourdes Gutiérrez‐Xicoténcatl, Fernando Roger Esquivel-Guadarrama · 2019 · Frontiers in Immunology
28. Stabilized coronavirus spike stem elicits a broadly protective antibody
    Ching‐Lin Hsieh, Anne P. Werner, Sarah R. Leist, Laura J. Stevens, Ester Falconer, Jory A. Goldsmith, Chia‐Wei Chou, Olubukola M. Abiona, Ande West, Kathryn Westendorf et al. · 2021 · Cell Reports
29. Can follicular helper T cells be targeted to improve vaccine efficacy?
    Michelle A. Linterman, Danika Lea Hill · 2016 · F1000Research
30. Generation and Protective Ability of Influenza Virus–Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge
    Sinthujan Jegaskanda, Catherine J. Luke, Heather D. Hickman, Mark Y. Sangster, Wendy Wieland‐Alter, Jacqueline McBride, Jonathan Wilson Yewdell, Peter F. Wright, John Jay Treanor, Carrie M. Rosenberger et al. · 2016 · The Journal of Infectious Diseases
31. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection
    Dubravka Grdic Eliasson, Ajibola Omokanye, Karin Schön, Ulf Alexander Wenzel, Valentina Bernasconi, Mats Bemark, Annasaheb B. Kolpe, Karim El Bakkouri, Tine Ysenbaert, Lei Deng et al. · 2017 · Mucosal Immunology
32. Hemagglutinin Structure and Activities
    Steve J. Gamblin, Sebastien G. Vachieri, Xiaoli Xiong, Jie Zhang, Stephen R. Martin, John James Skehel · 2020 · Cold Spring Harbor Perspectives in Medicine
33. Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus
    Maya Sangesland, Larance Ronsard, Samuel W. Kazer, Julia Bals, Seyhan Boyoglu-Barnum, Ashraf Siddig Yousif, Ralston M. Barnes, Jared E. Feldman, Maricel Quirindongo-Crespo, Patrick M. McTamney et al. · 2019 · Immunity
34. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry
    Corey Momont, Ha V. Dang, Fabrizia Zatta, Kevin Hauser, Caihong Wang, Julia di Iulio, Andrea Minola, Nadine Czudnochowski, Anna De Marco, Kaitlin Branch et al. · 2023 · Nature
35. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies
    Magdalena Sips, Marina Krykbaeva, T.J. Diefenbach, Musie S Ghebremichael, Brittany A. Bowman, A Dugast, A.W. Boesch, Hendrik Streeck, Douglas S. Kwon, Margaret E. Ackerman et al. · 2016 · Mucosal Immunology
36. Treating Influenza Infection, From Now and Into the Future
    Sophia Davidson · 2018 · Frontiers in Immunology
37. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections
    Hilal Ahmad Parray, Shivangi Shukla, Reshma Perween, Ritika Khatri, Tripti Shrivastava, Vanshika Singh, Praveenkumar Murugavelu, Shubbir Ahmed, Sweety Samal, Chandresh Sharma et al. · 2021 · Applied Microbiology and Biotechnology
38. Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine
    Carolyn M. Boudreau, Galit Alter · 2019 · Frontiers in Immunology
39. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
    Dennis Lapuente, Thomas Winkler, Matthias Tenbusch · 2023 · Cellular and Molecular Immunology
40. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
    Saborni Chakraborty, Vamsee V. A. Mallajosyula, Cristina M. Tato, Gene S. Tan, Taia T. Wang · 2021 · Advanced Drug Delivery Reviews
41. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model
    Megan E. Ermler, Ericka Kirkpatrick Roubidoux, Weina Sun, Rong Hai, Fatima Amanat, Veronika Chromikova, Peter Palese, Florian Krammer · 2017 · Journal of Virology
42. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
    Sarah Creytens, Mirte N. Pascha, Marlies Ballegeer, Xavier Saelens, Cornelis A. M. de Haan · 2021 · Frontiers in Immunology
43. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design
    José M. M. Caaveiro, Masato Kiyoshi, Kouhei Tsumoto · 2015 · Immunological Reviews
44. Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
    Yi Liu, Hyon‐Xhi Tan, Marios Koutsakos, Sinthujan Jegaskanda, Robyn Esterbauer, Danielle Tilmanis, Malet Aban, Katherine Kedzierska, Aeron C. Hurt, Stephen John Kent et al. · 2019 · Nature Communications
45. Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms
    Kashyap Patel, Jacob T. Roberts, Adam W. Barb · 2019 · Frontiers in Immunology
46. Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies
    Ivan Košík, Davide Angeletti, James S. Gibbs, Matthew Angel, Kazuyo Takeda, Martina Košíková, Vinod Nair, Heather D. Hickman, Hang Xie, Christopher B. Brooke et al. · 2019 · The Journal of Experimental Medicine
47. Influenza and Antibody-Dependent Cellular Cytotoxicity
    Tarra A. Von Holle, Michael Anthony Moody · 2019 · Frontiers in Immunology
48. Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine
    Lynda Coughlan, Peter Palese · 2018 · Cell Host & Microbe
49. Emerging influenza viruses and the prospect of a universal influenza virus vaccine
    Florian Krammer · 2015 · Biotechnology Journal
50. Influenza Vaccines: Successes and Continuing Challenges
    Tanja Becker, Husni Elbahesh, Leslie A. Reperant, Guus F. Rimmelzwaan, Albert D. M. E. Osterhaus · 2021 · The Journal of Infectious Diseases
51. A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve
    Ying Fu, Zhen Zhang, Jared Sheehan, Yuval Avnir, Callie A. Ridenour, Thomas Sachnik, Jiusong Sun, M. Jaber Hossain, Li-Mei Chen, Quan Karen Zhu et al. · 2016 · Nature Communications
52. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses
    Teddy John Wohlbold, Raffael Nachbagauer, Irina Margine, Gene S. Tan, Ariana Hirsh, Florian Krammer · 2015 · Vaccine
53. Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets
    Raffael Nachbagauer, Matthew S. Miller, Rong Hai, Alex B. Ryder, John K. Rose, Peter Palese, Adolfo García‐Sastre, Florian Krammer, Randy A. Albrecht · 2015 · Journal of Virology
54. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes
    Julie M. Fox, Vicky Roy, Bronwyn M. Gunn, Ling Huang, Melissa Anne Edeling, Matthias Mack, Daved H. Fremont, Benjamin J. Doranz, Syd Johnson, Galit Alter et al. · 2019 · Science Immunology
55. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective
    Anders Madsen, Ya-Nan Dai, Meagan McMahon, Aaron J. Schmitz, Jackson S. Turner, Jessica Tan, Tingting Lei, Wafaa B. Alsoussi, Shirin Strohmeier, Mostafa Amor et al. · 2020 · Immunity
56. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice
    Asthagiri Arunkumar, Guha, Ioannou, Andriani, Wohlbold, Teddy John, Meade, Philip, Aslam, Sadaf, Amanat, Fatima, Ayllon, Juan, García-Sastre, Adolfo, Krammer, Florian · 2019 · Journal of Virology
57. Modulating Antibody Functionality in Infectious Disease and Vaccination
    Bronwyn M. Gunn, Galit Alter · 2016 · Trends in Molecular Medicine
58. Systems serology for evaluation of HIV vaccine trials
    Margaret E. Ackerman, Dan H. Barouch, Galit Alter · 2017 · Immunological Reviews
59. Meeting report and review: Immunological assays and correlates of protection for next‐generation influenza vaccines
    Florian Krammer, Jerry P. Weir, Othmar G. Engelhardt, Jacqueline M. Katz, Rebecca Jane Cox · 2019 · Influenza and Other Respiratory Viruses
60. Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity
    James T. Earnest, Katherine Basore, Vicky Roy, Adam L. Bailey, David Wang, Galit Alter, Daved H. Fremont, Michael S. Diamond · 2019 · The Journal of Experimental Medicine
61. Therapeutic Vaccines for Tuberculosis: An Overview
    Rania Bouzeyen, Babak Javid · 2022 · Frontiers in Immunology
62. Tackling COVID-19 with neutralizing monoclonal antibodies
    Corti, Davide, Purcell, Lisa A., Snell, Gyorgy, Veesler, David · 2021 · Cell
63. Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus
    Stephanie Ascough, Suzanna Paterson, Christopher Chiu · 2018 · Frontiers in Immunology
64. Drugs for Influenza Treatment: Is There Significant News?
    Nicola Principi, Barbara Camilloni, Anna Alunno, Ilaria Polinori, Alberto Argentiero, Susanna Esposito · 2019 · Frontiers in Medicine
65. The Quest for a Truly Universal Influenza Vaccine
    Yo Han Jang, Baik Lin Seong · 2019 · Frontiers in Cellular and Infection Microbiology
66. Mechanisms and targets of Fcγ-receptor mediated immunity to malaria sporozoites
    Gaoqian Feng, Bruce D. Wines, Liriye Kurtovic, Jo-Anne Chan, Philippe Boeuf, Vanessa Mollard, Anton J. Cozijnsen, Damien R. Drew, Daniel L. Marshall, Sandra Chishimba et al. · 2021 · Nature Communications
67. Mice with diverse microbial exposure histories as a model for preclinical vaccine testing
    Jessica K. Fiege, Katharine E. Block, Mark J. Pierson, Hezkiel A. Nanda, Frances K. Shepherd, Clayton K. Mickelson, James Michael Stolley, William E. Matchett, Sathi Wijeyesinghe, David Kyle Meyerholz et al. · 2021 · Cell Host & Microbe
68. Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates
    Tomer Zohar, Jeff C. Hsiao, Nickita Mehta, Jishnu Das, Anush Devadhasan, Wiktor Karpinski, Cheryl Callahan, Michael P. Citron, Daniel J. DiStefano, Sinoeun Touch et al. · 2021 · Cell Host & Microbe
69. Broadly Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones
    Wenqian He, Caitlin E. Mullarkey, J. Andrew Duty, Thomas M. Moran, Peter Palese, Matthew S. Miller · 2015 · Journal of Virology
70. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins
    Hillary A. Vanderven, Fernanda Ana‐Sosa‐Batiz, Sinthujan Jegaskanda, Steven P. Rockman, Karen Laurie, Ian Barr, Weisan Chen, Bruce D. Wines, Philip Mark Hogarth, Teresa Lambe et al. · 2016 · EBioMedicine
71. Systems serology: profiling vaccine induced humoral immunity against HIV
    Amy W. Chung, Galit Alter · 2017 · Retrovirology
72. Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire
    Yariv Wine, Andrew P. Horton, Gregory C. Ippolito, George Georgiou · 2015 · Current Opinion in Immunology
73. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
    Suryadevara, Naveenchandra, Shrihari, Swathi, Gilchuk, Pavlo, VanBlargan, Laura A., Binshtein, Elad, Zost, Seth J., Nargi, Rachel S., Sutton, Rachel E., Winkler, Emma S., Chen, Elaine C. et al. · 2021
74. Direct Administration in the Respiratory Tract Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies
    Victor Hugo Leyva-Grado, Gene S. Tan, Paul E. Leon, Mark A. Yondola, Peter Palese · 2015 · Antimicrobial Agents and Chemotherapy
75. Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies
    Silvie Van den Hoecke, Katrin Ehrhardt, Annasaheb B. Kolpe, Karim El Bakkouri, Lei Deng, Hendrik Grootaert, Steve Schoonooghe, Anouk Smet, Mostafa Bentahir, Kenny Roose et al. · 2017 · Journal of Virology
76. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
    Surender Khurana, Elizabeth M. Coyle, Jody F. Manischewitz, Lisa R. King, Jin Gao, Ronald N. Germain, Pamela L. Schwartzberg, John S. Tsang, Hana Golding, Angélique Biancotto et al. · 2018 · npj Vaccines
77. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
    Sofia E. Magnusson, Arwen F. Altenburg, Karin Lövgren Bengtsson, Fons Bosman, Rory D. de Vries, Guus F. Rimmelzwaan, Linda Stertman · 2018 · Immunologic Research
78. Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza Viruses
    Sinthujan Jegaskanda, Kirsten L. Vandenberg, Karen Laurie, Liyen Loh, Marit Kramski, Wendy R. Winnall, Katherine Kedzierska, Steven P. Rockman, Stephen John Kent · 2014 · The Journal of Infectious Diseases
79. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo
    Pengfei Wang, Mili R. Gajjar, Jian Yu, Neal N. Padte, Agegnehu Gettie, James Blanchard, Kasi Russell‐Lodrigue, Laura E. Liao, Alan S. Perelson, Yaoxing Huang et al. · 2020 · Proceedings of the National Academy of Sciences
80. Antibody-dependent cellular cytotoxicity and influenza virus
    Hillary A. Vanderven, Sinthujan Jegaskanda, Adam K. Wheatley, Stephen John Kent · 2017 · Current Opinion in Virology
81. Development of Influenza B Universal Vaccine Candidates Using the “Mosaic” Hemagglutinin Approach
    Weina Sun, Ericka Kirkpatrick Roubidoux, Megan E. Ermler, Raffael Nachbagauer, Felix Broecker, Florian Krammer, Peter Palese · 2019 · Journal of Virology
82. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview
    Manasik Gumah Ali, Zhening Zhang, Qi Gao, Mingzhu Pan, Edward G. Rowan, Juan Zhang · 2020 · Immunologic Research
83. Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination
    Carolyn M. Boudreau, Wen‐Han Yu, Todd J. Suscovich, H. Keipp Talbot, Kathryn M. Edwards, Galit Alter · 2019 · Journal of Clinical Investigation
84. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis
    Nadja Kern, Rui Dong, Shawn M. Douglas, Ronald D. Vale, Meghan A. Morrissey · 2021 · eLife
85. Noninvasive Visualization of Respiratory Viral Infection Using Bioorthogonal Conjugated Near-Infrared-Emitting Quantum Dots
    Hong Pan, Pengfei Zhang, Duyang Gao, Yijuan Zhang, Ping Li, Lanlan Liu, Ce Wang, Hanzhong Wang, Yifan Ma, Lintao Cai · 2014 · ACS Nano
86. IgA potentiates NETosis in response to viral infection
    Hannah D. Stacey, Diana Golubeva, Alyssa Posca, Jann Catherine Ang, Kyle E. Novakowski, Muhammad Atif Zahoor, Charu Kaushic, Ewa Cairns, Dawn M. E. Bowdish, Caitlin E. Mullarkey et al. · 2021 · Proceedings of the National Academy of Sciences
87. Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
    Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov · 2022 · Molecular Therapy
88. Alternative Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a V H 3-30-Encoded Heterosubtypic Antibody
    Arkadiusz Wyrzucki, Cyrille Dreyfus, Ines Kohler, Marco Steck, Ian A. Wilson, Lars Hangartner · 2014 · Journal of Virology
89. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
    Alysia A. Ahmed, Sravya Keremane, Jost Vielmetter, Pamela J. Björkman · 2016 · Journal of Structural Biology
90. A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections
    Aitor Nogales, Ginés Ávila‐Pérez, Javier Rangel‐Moreno, Kevin Chiem, Marta L. DeDiego, Luis Martínez‐Sobrido · 2019 · Journal of Virology
91. Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine
    Brianna L. Bullard, Eric A. Weaver · 2021 · Vaccines
92. Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection
    Antônio Gregorio Dias, Caroline G. Atyeo, Carolin Loos, Magelda Montoya, Vicky Roy, Sandra Bos, Parnal Narvekar, Tulika Singh, Leah C. Katzelnick, Guillermina M. Kuan et al. · 2022 · Science Translational Medicine
93. Suppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection
    Douglas H. Yamada, Heidi J. Elsaesser, Anja Lux, John M. Timmerman, Sherie Leaver Morrison, Juan Carlos de la Torre, Falk Nimmerjahn, David G. Brooks · 2015 · Immunity
94. Influenza-Specific Antibody-Dependent Phagocytosis
    Fernanda Ana‐Sosa‐Batiz, Hillary A. Vanderven, Sinthujan Jegaskanda, Angus P. R. Johnston, Steven P. Rockman, Karen Laurie, Ian Barr, Patrick C. Reading, Marit Lichtfuss, Stephen John Kent · 2016 · PLoS ONE
95. Antibody-guided vaccine design: identification of protective epitopes
    Antonio Lanzavecchia, Alexander Frühwirth, Laurent H. Perez, Davide Corti · 2016 · Current Opinion in Immunology
96. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection
    de Vries, Rory D., Nieuwkoop, Nella J., Pronk, Mark, de Bruin, Erwin, Leroux-Roels, Geert, Huijskens, Elisabeth G.W., van Binnendijk, Rob S., Krammer, Florian, Koopmans, Marion P.G., Rimmelzwaan, Guus F. · 2017 · Vaccine
97. Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
    Athena P. Y. Li, Carolyn A. Cohen, Nancy Leung, Vicky J. Fang, Shivaprakash Gangappa, Suryaprakash R. Sambhara, Min Z. Levine, Angela Danielle Iuliano, Ranawaka A. P. M. Perera, Dkm Ip et al. · 2021 · npj Vaccines
98. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus
    Bronwyn M. Gunn, Richard Lu, Matthew D. Slein, Philipp A. Ilinykh, Kai Huang, Caroline G. Atyeo, Sharon L. Schendel, Jiyoung Kim, Caitlin J. Cain-Trivette, Vicky Roy et al. · 2020 · Immunity
99. Broadly Neutralizing Influenza Hemagglutinin Stem-Specific Antibody CR8020 Targets Residues that Are Prone to Escape due to Host Selection Pressure
    Kannan Tharakaraman, Vidya Subramanian, David Cain, Viswanathan Sasisekharan, Ram Sasisekharan · 2014 · Cell Host & Microbe
100. Structure of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus in Complex with a Protective Monoclonal Antibody
     Ki Joon Cho, Bert Schepens, Jong Hyeon Seok, Sella Kim, Kenny Roose, Jihye Lee, Rodrigo U. Gallardo, Evelien Van Hamme, Joost W. H. Schymkowitz, Frédéric Rousseau et al. · 2015 · Journal of Virology